None
Quote | The Ultimate Software Group Inc. (NASDAQ:ULTI)
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $331.36 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | The Ultimate Software Group Inc. (NASDAQ:ULTI)
Full recruitment of 154 patients with malignant melanoma in U.S. and Europe in 24 months Study provides randomized data on impact of UV1 on standard-of-care immunotherapy Topline progression-free survival data expected H1 2023 Oslo, 30 June 202 2 : ...
Oslo, 21. March 2022 : Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced that it will host a key opinion leader (KOL) webinar on the unmet need and treatment landscape of melanoma on Monday, March 28, 2...
Message Board Posts | The Ultimate Software Group Inc. (NASDAQ:ULTI)
Subject | By | Source | When |
---|---|---|---|
News: $ULTI National Operator of Burger King, Popeyes | whytestocks | investorshub | 01/24/2019 7:36:21 PM |
Take a look at recent $TYL presentation on | ranchhand71 | investorshub | 06/18/2018 10:20:07 PM |
That was a great call by BofA. Trades | dave7933 | investorshub | 06/13/2018 3:55:51 PM |
BOA initiates at underperform at $187. Lol. This | buylosellhi | investorshub | 11/06/2017 4:39:06 PM |
Great trading opportunity with this stock. It goes | buylosellhi | investorshub | 11/03/2017 3:27:51 PM |
News, Short Squeeze, Breakout and More Instantly...
The Ultimate Software Group Inc. Company Name:
ULTI Stock Symbol:
NASDAQ Market:
Full recruitment of 154 patients with malignant melanoma in U.S. and Europe in 24 months Study provides randomized data on impact of UV1 on standard-of-care immunotherapy Topline progression-free survival data expected H1 2023 Oslo, 30 June 202 2 : ...
Oslo, 21. March 2022 : Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced that it will host a key opinion leader (KOL) webinar on the unmet need and treatment landscape of melanoma on Monday, March 28, 2...
Oslo, 1 7 February 202 2 : Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its fourth quarter 2021 results today. The presentation by the company's management team can be followed as a liv...